Clinical Trials Directory

We are doing this study to find out if a study drug called ivosidenib is a safe and effective option for locally advanced or metastatic conventional chondrosarcoma with an isocitrate dehydrogenase 1 (IDH1) mutation.

In this study, people will take a medicine called S241656 by mouth. They may take it by itself or with other cancer treatments, and they may take it once or twice a day depending on their study group. The study has two parts. In Part 1, people receive different amounts of the medicine so researchers can find the safest dose. In Part 2, people receive the safest dose that was found in Part 1. Participants will keep taking the medicine until their cancer gets worse or the side effects become too strong or happen too often. During the study, they will visit the clinic regularly and have many tests, including blood tests, urine tests, and scans. The whole study is expected to last about five years.

We are doing this study to find out if an experimental drug combination made up of ivosidenib, gemcitabine, cisplatin, and durvalumab is a safe and effective for treating cholangiocarcinoma.

In this study, participants will complete two or three in-person visits where they answer surveys and walk for six minutes. After that, they will be placed into one of two groups. One group will start the exercise and nutrition program right away, and the other group will start the program later. The program lasts for twelve weeks. During this time, there will be classes three times each week that last one hour. There will also be a nutrition session every other week. Participants do not need to attend every session, but they are asked to come to at least two thirds of the classes.

As part of the study, you'll get your regular CT scan, plus a few extra pictures just for the study. You'll also get an MRI, either on the same day or another day—whichever works best for you. On the same day as your MRI, you’ll also get an ultrasound. If you haven’t had a certain blood test called a hematocrit test in the last day, you’ll get a small blood test during your CT scan to check how healthy your liver is.

We are doing this study to learn more about the connection between the brain and leg muscles in people who have chronic stroke. We want to understand how this connection affects the walking abilities of chronic stroke patients so we can provide better help to stroke patients who need to improve their motor function.

People in the study will have one visit that lasts about 20 minutes. During this visit, the researchers will ask for basic information like age, gender, and race or ethnicity. They will also look at skin color using a special chart called the Monk Skin Tone scale. Next, trained workers will use a small device called the InfraScanner 2500TM to check different parts of the head. These parts include the front, sides, and back. The device is safe, approved by the FDA, and does not use harmful radiation. It uses light to do its job and does not hurt. This study does not give medicine, does not pick people randomly, and does not share test results with the participants.

We are doing this study to find out if an experimental drug called PT217 (the study drug) is a safe and effective option for people who have neuroendocrine carcinomas. We want to see how this drug works when it is given on its own and in combination with standard chemotherapy and/or immunotherapy drugs.